Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Get Free Report) (TSE:AUP) have received an average rating of “Hold” from the six ratings firms that are covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $17.6667.
AUPH has been the topic of a number of recent research reports. Zacks Research lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 21st. Weiss Ratings reissued a “hold (c+)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday. Wall Street Zen cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Royal Bank Of Canada upped their price objective on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a report on Friday, August 7th.
Read Our Latest Research Report on AUPH
Insider Activity
Hedge Funds Weigh In On Aurinia Pharmaceuticals
A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at about $139,037,000. Arrowstreet Capital Limited Partnership increased its holdings in shares of Aurinia Pharmaceuticals by 213.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,374,021 shares of the biotechnology company’s stock valued at $37,283,000 after purchasing an additional 2,297,903 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Aurinia Pharmaceuticals by 1,272.5% during the 3rd quarter. Marshall Wace LLP now owns 1,483,132 shares of the biotechnology company’s stock valued at $16,389,000 after purchasing an additional 1,375,072 shares in the last quarter. Kotler Kevin acquired a new position in shares of Aurinia Pharmaceuticals in the 4th quarter valued at $19,536,000. Finally, Two Sigma Investments LP lifted its stake in shares of Aurinia Pharmaceuticals by 728.6% in the 3rd quarter. Two Sigma Investments LP now owns 1,341,067 shares of the biotechnology company’s stock valued at $14,819,000 after purchasing an additional 1,179,219 shares during the period. Hedge funds and other institutional investors own 36.83% of the company’s stock.
Aurinia Pharmaceuticals Stock Performance
Shares of AUPH opened at $15.47 on Friday. The stock has a 50-day moving average of $15.91 and a two-hundred day moving average of $15.38. Aurinia Pharmaceuticals has a one year low of $10.34 and a one year high of $19.25. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.97 and a current ratio of 5.42. The stock has a market cap of $2.06 billion, a P/E ratio of 6.76 and a beta of 1.42.
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%.The business had revenue of $58.57 million for the quarter, compared to analyst estimates of $80.45 million. As a group, research analysts predict that Aurinia Pharmaceuticals will post 0.79 EPS for the current year.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.
The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.
Featured Stories
- Five stocks we like better than Aurinia Pharmaceuticals
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
